Acne – Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Acne – Pipeline Review, Q1 2011', provides an overview of the Acne therapeutic pipeline. This report provides information on the therapeutic development for Acne, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne. 'Acne – Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope A snapshot of the global therapeutic scenario for Acne. A review of the Acne products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Coverage of products based on various stages of development ranging from discovery till registration stages. A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Coverage of the Acne pipeline on the basis of therapeutic class, route of administration and molecule type. Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons to buy Identify and understand important and diverse types of therapeutics under development for Acne. Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. Plan mergers and acquisitions effectively...
Acne And Related Disorders – Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Acne Pipeline Review, Q4 2010”, provides an overview of the Acne therapeutic pipeline. This report provides information on the therapeutic development for Acne, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne. “Acne-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. ScopeA snapshot of the global therapeutic scenario for Acne.A review of the Acne products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Coverage of products based on various stages of development ranging from discovery till registration stages.A feature on pipeline projects on the basis of monotherapy and combined therapeutics.Coverage of the Acne pipeline on the basis of therapeutic class, route of administration and molecule type.Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.Key discontinued pipeline projects.Latest news and deals relating to the products.Reasons to buyIdentify and understand important and diverse types of therapeutics under development for Acne.Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.Devise corrective measures for pipeline projects by understanding Acne pipeline depth and focus of Acne therapeutics. Develop and design in-licensing and out-licensing strategies by identifying...
Acne Vulgaris – Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Acne Vulgaris Pipeline Review, Q4 2010”, provides an overview of the Acne Vulgaris therapeutic pipeline. This report provides information on the therapeutic development for Acne Vulgaris, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne Vulgaris. “Acne Vulgaris-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. ScopeA snapshot of the global therapeutic scenario for Acne Vulgaris.A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Coverage of products based on various stages of development ranging from discovery till registration stages.A feature on pipeline projects on the basis of monotherapy and combined therapeutics.Coverage of the Acne Vulgaris pipeline on the basis of therapeutic class, route of administration and molecule type.Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.Key discontinued pipeline projects.Latest news and deals relating to the products.Reasons to buyIdentify and understand important and diverse types of therapeutics under development for Acne Vulgaris.Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Acne Vulgaris therapeutics....
